- Home
- TEO vs CELC Comparison
TEO vs CELC Comparison
Compare TEO & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEO
- CELC
- Stock Information
- Founded
- TEO 1979
- CELC 2011
- Country
- TEO Argentina
- CELC United States
- Employees
- TEO N/A
- CELC N/A
- Industry
- TEO Telecommunications Equipment
- CELC Medical Specialities
- Sector
- TEO Telecommunications
- CELC Health Care
- Exchange
- TEO Nasdaq
- CELC Nasdaq
- Market Cap
- TEO 2.9B
- CELC 2.3B
- IPO Year
- TEO N/A
- CELC 2017
- Fundamental
- Price
- TEO $7.48
- CELC $46.54
- Analyst Decision
- TEO Hold
- CELC Strong Buy
- Analyst Count
- TEO 2
- CELC 6
- Target Price
- TEO $10.60
- CELC $63.00
- AVG Volume (30 Days)
- TEO 334.2K
- CELC 996.1K
- Earning Date
- TEO 11-06-2025
- CELC 11-13-2025
- Dividend Yield
- TEO 2.64%
- CELC N/A
- EPS Growth
- TEO N/A
- CELC N/A
- EPS
- TEO N/A
- CELC N/A
- Revenue
- TEO $4,338,754,502.00
- CELC N/A
- Revenue This Year
- TEO $91.61
- CELC N/A
- Revenue Next Year
- TEO $10.21
- CELC N/A
- P/E Ratio
- TEO N/A
- CELC N/A
- Revenue Growth
- TEO 11.12
- CELC N/A
- 52 Week Low
- TEO $6.43
- CELC $7.58
- 52 Week High
- TEO $15.54
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- TEO 46.06
- CELC 43.89
- Support Level
- TEO $6.93
- CELC $47.43
- Resistance Level
- TEO $7.85
- CELC $50.11
- Average True Range (ATR)
- TEO 0.38
- CELC 3.01
- MACD
- TEO 0.09
- CELC -0.87
- Stochastic Oscillator
- TEO 48.72
- CELC 19.78
About TEO Telecom Argentina SA
Telecom Argentina SA offers its customers quadruple play services, combining mobile telephony services, cable television services, Internet services and fixed telephony services. It also provides other telephone-related services such as international long-distance and wholesale services, data transmission and IT solutions outsourcing and install, operate and develop cable television and data transmission services. The company provides services in Argentina (mobile, cable television, Internet and fixed and data services), Paraguay (mobile, Internet and satellite TV services), Uruguay (cable television services), the United States (fixed wholesale services) and Chile (Cybersecurity services and products).
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.